KAS
ALNY icon

Kemnay Advisory Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kemnay Advisory Services’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.5K Buy
53
+1
+2% +$340 ﹤0.01% 763
2025
Q4 		$20.7K Buy
+52
New +$23K ﹤0.01% 534
2020
Q2 		– Sell
-12,356
Closed -$1.34M – 84
2020
Q1 		$1.34M Buy
+12,356
New +$1.43M 0.38% 24

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kemnay Advisory Services's ALNY Position: Q1 2026 in Review

Kemnay Advisory Services increased its Alnylam Pharmaceuticals (ALNY) stake by 1.9% in Q1 2026, buying an estimated $340 and bringing the position to 53 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #763.

Kemnay Advisory Services first reported a position in ALNY in Q1 2020 and has held it in 3 quarters since. The position peaked at $1.34M in Q1 2020. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Kemnay Advisory Services held 53 shares of Alnylam Pharmaceuticals worth $17.5K as of Q1 2026.
  • Kemnay Advisory Services bought 1 Alnylam Pharmaceuticals share in Q1 2026, an estimated $340.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q1 2026, its #763 holding.
  • Kemnay Advisory Services first reported a position in Alnylam Pharmaceuticals in Q1 2020 and has held it in 3 quarters since.
  • Kemnay Advisory Services's Alnylam Pharmaceuticals position peaked at $1.34M in Q1 2020.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Kemnay Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.